transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Reducing Adverse Effects During Drug Development: The Example of Lesogaberan and Paresthesia

Författare och institution:
H. Rydholm (-); Fredrik von Corswant (-); H. Denison (-); J. M. Jensen (-); Anders Lehmann (Institutionen för neurovetenskap och fysiologi); Magnus Ruth (Institutionen för kliniska vetenskaper); E. Soderlind (-); A. Aurell-Holmberg (-)
Publicerad i:
Clinical Therapeutics, 38 ( 4 ) s. 946-960
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
Purpose: Lesogaberan, a gamma-aminobutyric acid (GABA)(B) receptor agonist, was developed for the treatment of gastroesophageal reflux disease in patients with a partial response to proton pump inhibitor therapy. A high prevalence of paresthesia was observed in healthy individuals after dosing with lesogaberan in early-phase clinical trials. The aim of this review was to gain further insight into paresthesia caused by lesogaberan by summarizing the relevant preclinical and clinical data. Methods: This study was a narrative review of the literature and unpublished data. Findings: The occurrence of paresthesia may depend on the route or rate of drug administration; several studies were conducted to test this hypothesis, and formulations were developed to minimize the occurrence of paresthesia. Phase I clinical studies showed that, in healthy individuals, paresthesia occurred soon after administration of lesogaberan in a dose-dependent manner regardless of the route of administration. The occurrence of paresthesia could be decreased by fractionating the dose or reducing the rate of administration. These findings suggest that the initial rate of absorption plays an important part in the development of paresthesia. Modified-release formulations minimize the occurrence of paresthesia while retaining the anti-reflux activity of the drug, as measured by esophageal pH and the number of transient lower esophageal sphincter relaxations. Implications: The development of lesogaberan was halted because the effect on gastroesophageal reflux disease symptoms observed in Phase II studies was not considered clinically meaningful in the target patient population. Nevertheless, it is an example of successful formulation development designed to minimize the occurrence of a compound's adverse effect while retaining its pharmacodynamic action. (C) 2016 Elsevier HS Journals, Inc. All rights reserved.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin
gamma-aminobutyric acid (GABA)(B) receptor agonist, adverse-effect, formulation development, gastroesophageal-reflux disease, esophageal sphincter relaxations, pump, inhibitor therapy, controlled-trial, volunteers, mechanism, symptoms, agonist, Pharmacology & Pharmacy, nt j, 1980, journal of clinical investigation, v65, p256
Postens nummer:
Posten skapad:
2016-06-09 15:14

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007